Pavmed Inc C/Wts 30/04/2024(To Pur Com) Class Z News

Buy Rating Affirmed for PAVmed on Growth and Valuation Prospects Amidst Product Commercialization

TipRanksApr 15 17:16

Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target

TipRanksMar 29 19:46

Analysts Offer Insights on Healthcare Companies: PAVmed (PAVM) and Simulations Plus (SLP)

TipRanksMar 28 21:20

Cantor Fitzgerald Reiterates Neutral on PAVmed, Maintains $1.4 Price Target

BenzingaAug 18, 2023 22:46

PAVmed Analyst Ratings

BenzingaAug 18, 2023 22:45

PAVmed (PAVM) Receives a Buy From Maxim Group

TipRanksAug 18, 2023 19:45

Maxim Group Remains a Buy on PAVmed (PAVM)

TipRanksMay 19, 2023 03:35

Ascendiant Sticks to Its Buy Rating for PAVmed (PAVM)

TipRanksApr 12, 2023 15:10

Cantor Fitzgerald Downgrades PAVmed to Neutral From Overweight, Cuts Price Target to $1.50 From $4

MT NewswiresJan 20, 2023 21:38

PAVmed Analyst Ratings

Benzinga Analyst RatingsJan 20, 2023 20:46

Lake Street Adjusts PAVmed's Price Target to $1.50 From $5, Maintains Buy Rating

MT NewswiresJan 19, 2023 09:58

PAVmed Analyst Ratings

Benzinga Analyst RatingsJan 18, 2023 22:41

Lake Street Maintains Buy on PAVmed, Lowers Price Target to $1.5

Benzinga Real-time NewsJan 18, 2023 22:41